TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: mean change in Overcontrol composite score of EDI-3
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Hospitalization due to COVID-19
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: LDL-C target achieving rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Benefit of Double Umbilical Cord Blood Units Stem Cell Transplantation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Side Effects of Double Umbilical Cord Blood Units Stem Cell Transplantation
Endpoint domain: Adverse events/effects
Primary endpoint: Change from baseline in urinary albumin to creatine ratio (UACR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Disease free time
Endpoint domain: Mortality/survival
Primary endpoint: Prevalence of active and latent yaws
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Serum concentration of tigecycline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adherence to medications scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Knowledge about chronic medications scores
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Death or initiation of ECMO
Endpoint domain: Mortality/survival
Primary endpoint: cholera-related diarrhea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of infectious events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Degree of flexion of lumbar spine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in cognitive development
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in motor development
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in social-emotional development
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Diagnostic value of EBUS-GS-TBLB
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Assessment of the occurrence of anti-sarilumab antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Assessment of the titer of anti-sarilumab antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Frequency of Musculoskeletal complaints
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Values of Pain intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Values of Self-perceived Health
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Grayscale Curve Fitting
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Contact lens centration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Irritability subscale of the Aberrant Behavior Checklist
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Lersivirine Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)]
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lersivirine Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lersivirine Maximum Observed Plasma Concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Procedure Start
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Fourfold Table Analysis Indexes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Geographic Atrophy (GA) Lesion Area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 4 Hour Mortality
Endpoint domain: Mortality/survival
Primary endpoint: Statistical Parametric Map from fMRI data on brainstem level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Statistical Parametric Map from fMRI data in the thalamus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Statistical Parametric Map from fMRI data in the insula
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Bone tunnel width
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical efficacy (WOMAC, IKDC 2000)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in MAT-sf score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change from the Spanish Fibromyalgia Impact Questionnaire (SFIQ)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change from Visual Analogue Scale (VAS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change from Borg Scale of perceived exertion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fatty acid status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Overall Wrinkle Severity Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in overall facial appearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of recurrent Clostridium difficile infection
Endpoint domain: Adverse events/effects
Primary endpoint: AUC (0-t) of etanercept
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the semaglutide plasma concentration curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Donor Cell Engraftment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Average Aligner Tracking Percentage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in subtotal storage symptoms score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence/Duration of atrial and tachyarrhythmias
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: F2-isoprostanes levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in total weekly number of incontinence episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Glucoregulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: absolute beat-to-beat BP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: subject perceived efficacy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of hematopoietic patients with anti-HPA antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percentage of Participants With Treatment-Emergent Adverse Events (AEs) And Serious Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Serum anti-Müllerian hormone (AMH) level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in size of FAZ
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Comparison of CNVs distributions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in HOMA-IR index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Participants Who Received Concomitant Treatment Strategies to Manage Palmar-Plantar Erythrodysesthesia (PPE)
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of Participants That Received Curative Treatment and/or Prophylaxis Treatment for PPE
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Composite Endpoint of Reduction in Estimated GFR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: ESRD or Death
Endpoint domain: Mortality/survival
Primary endpoint: Progression free survival rate at one year
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of Major Cardiovascular Events (MACE)
Endpoint domain: Mortality/survival
Primary endpoint: Reliability of trunk tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: fat free mass (FFM) measured by DXA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: fat free mass (FFM) measured by BodyMetrix ultrasound
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Level of (1,3)-Beta-D-Glucans
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: FertiQol score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Pacing impedances at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: R-wave amplitudes at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 6-month complication free rate
Endpoint domain: Adverse events/effects
Primary endpoint: Average plasma concentration of the drugs (TKIs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of deep venous thrombosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Impaired cerebrovascular reactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Presence of stigma
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Inter-method reliability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: lung injury after cardiac surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: kidney injury after cardiac surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Perioperative glucose level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Comparison of CT scan results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of CD4+Foxp3+ T cells expressing CD45RA and/or HLA-DR and/or ICOS and/or PD1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Frequency of CD4+Foxp3- T cells expressing CD45RA and/or HLA-DR and/or ICOS and/or PD1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Frequency of HBs- and HBc-specific CD4+Foxp3+ T cells expressing CD69 and/or LAP in Fresh Samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Neurological Performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change from baseline in IGA scale at 4 week-treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: The numbers of subjects with AE/SAE
Endpoint domain: Adverse events/effects
Primary endpoint: First Pass Success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Technical success of early esophageal cancer resection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: humoral immune response (anti-Haemmagglutinin antibodies)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Maximum plasma concentration (Cmax) of Simvastatin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serotonin Release Assay
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Heparin/platelet factor 4 antibody
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of patients with grade 3 or 4 complications
Endpoint domain: Adverse events/effects
Primary endpoint: Fold Change in Plasma Very Low Density Lipoprotein (VLDL) Triglyceride Palmitate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Oral tolerance to selected tree nuts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 24-hour Area Under the Curve for Blood Ammonia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Rate of Total Lipolysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Rate of Net Lipolysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Work Engagement
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Affective States
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Psychological Well-Being
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes in blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Changes in blood volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of Participants With Virologic Failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Delayed ischemic neurological deficit
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Score of the Barthel Index
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Improvement rate of PASI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Pain clinical relief
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional disability index improvement
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: MRI testing results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: State-Trait Anxiety Inventory (STAI) Y2
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Clinical Outcomes in Routine Evaluation-Outcome Measure (CORE-OM)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Coping Orientations to Problem Experienced NVI - 25
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in quality of life as measured by AAQoL
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: SDS
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Time until recurrent ischemic stroke or systemic embolism
Endpoint domain: Mortality/survival
Primary endpoint: Time until the first haemorrhagic stroke
Endpoint domain: Mortality/survival
Primary endpoint: Number of Adverse events per treatment arm
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Complete Response at 3 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite complete remission (CRc) rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Clinical improvement in urge urinary incontinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Clinical improvement urinary frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Clinical improvement in degree of urgency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Area-under-the curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dietary Energy Density
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Annual inpatient healthcare utilization per 1000 patient years
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Annual emergency room healthcare utilization per 1000 patient years
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Annual outpatient visit healthcare utilization per patient per 1000 patient years
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Median duration of survival after diagnosis of lymphoma
Endpoint domain: Mortality/survival
Primary endpoint: Rate of Surgical Site Infection
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants That Discontinued Study Treatment Due to an Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: Impact of COPD on daily activities
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change from baseline 6-min walking distance to one year after ICU discharge
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline hand grip strength to one year after ICU discharge
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum inspiratory pressure, from baseline to one year after ICU discharge
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Total number of Day 5 embryos
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in bone turnover marker carboxy-terminal collagen crosslinks (CTx)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Efficacy 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy 2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ease of cervical dilatation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recovery from cardiogenic shock
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Total area under the plasma drug concentration-time curve (AUC 0-4 h)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Urinary excretion of tiotropium (Ae(0-4 hours))
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Renal clearance of tiotropium (CLren)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Terminal elimination half-life after the last dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tricuspid Regurgitant Jet Velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Stimulation of inflammatory parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Proportion of citizens at increased risk of lifestyle related disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rate of response to antidepressant therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hemostasis rate after EMR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: MRSA infection rates
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of BV-free woman
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and tolerability of AV650
Endpoint domain: Adverse events/effects
Primary endpoint: Clinical progression signs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Adverse events reported
Endpoint domain: Adverse events/effects
Primary endpoint: World Health Organization Quality of Life (WHOQL)-BREF
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change of intraocular pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Identification of genetic variants
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Confirmation of causality of genetic variants
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-assessed radiation safety climate
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Self-assessed radiation safety behavior
Endpoint domain: Life impact
Endpoint subdomain: Behavioral functioning
Primary endpoint: Self-assessed radiation safety knowledge and motivation
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Upper-Extremity Fugl-Meyer Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Morphine Equivalent Dose of Opioids
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 24-hour energy expenditure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Peritoneal bacterial contamination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Contamination in the rectal stump after wash-out
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Geometric Mean Concentrations (GMCs) of Clostridium Difficile Toxin A and Toxin B Specific Neutralizing Antibodies at Month 7
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants Reporting Local Reactions by Maximum Severity Within 7 Days After Vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants Reporting Systemic Events by Maximum Severity Within 7 Days After Vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: incidence of post traumatic stress disorders
Endpoint domain: Adverse events/effects
Primary endpoint: Inpatient Mortality
Endpoint domain: Mortality/survival